Drugs / Fluvirin
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04484532 | Oct 2017 → Jun 2022 | acute myeloid leukemia, myelodysplastic syndrome | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02438423 | Jun 2015 → Mar 2016 | influenza | Mark Prausnitz | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04025580 | Oct 2019 → Jan 2023 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00518453 | Jul → Aug 2007 | influenza | Novartis Vaccines | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01640327 | Jul → Aug 2012 | influenza | Novartis Vaccines | Completed | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01248208 Comparator | Sep 2010 → Sep 2011 | food allergy | Walter Reed Army Medical Center | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00464672 Comparator | Apr → Jul 2007 | influenza | Novartis | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01867021 Comparator | May → Dec 2013 | influenza | Novartis | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02872311 Comparator | Sep 2016 → Apr 2018 | — | Marshfield Clinic Research Foundation | Completed | No outcome recorded |
| — | NCT00902278 Comparator | Oct 2008 → Apr 2016 | — | University of Massachusetts, Worcester | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluvirin | “A Phase 3, Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Influenza Vaccine (Fluvirin®), Formulation...” NCT01640327 ↗9“a primarily European-marketed trivalent vaccine (Agrippal®, Novartis Vaccines), and a predominantly U.S.-marketed control trivalent vaccine (Fluvirin®, Novartis Vaccines)” PMID 22691101 ↗ Jun 2012 “received a single dose of inactivated influenza vaccine (fluvirin: 18 μg of haemagglutinin per H1N1 vaccine strain” PMID 28666680 ↗ Jun 2017 “Licensed and FDA approved Fluvirin vaccine to be administered to study participants” NCT02872311 ↗ “1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition” NCT00518453 ↗ “Fluvirin (age 4y and older)” NCT01248208 ↗ “Fluvirin” NCT04484532 ↗ |
| Modality | Vaccine | “two influenza subunit vaccines” PMID 22691101 ↗ Jun 2012 |
| Route | Intramuscular | “Adolescents and adults received one dose of vaccine intramuscularly, whereas children aged 3-8 years received two vaccine doses, administered 4 wk apart” PMID 22691101 ↗ Jun 2012 |